Mark Hahn - Nov 11, 2024 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role: Chief Financial Officer
Signature: /s/ Andrew Fisher, Attorney-in-Fact for Mark Hahn
Stock symbol: VRNA
Transactions as of: Nov 11, 2024
Transactions value $: -$12,000
Form type: 4
Date filed: 11/13/2024, 04:57 PM
Previous filing: Nov 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRNA	Ordinary Shares	Sale	-$12K	-2.4K	-0.02%	$5.00	14.3M	Nov 11, 2024	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 6, 2024.
F3	Consists of (i) 3,000,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 375,000 ADSs); and (ii) 11,291,336 Ordinary Shares underlying 1,411,417 ADSs.